Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.
http://www.priceseries.com/trade/AERI-Aerie-Pharmaceuticals-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019120320191230.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments